X
Xenon Pharmaceuticals Inc. (XENE)
NGM – Real vaqt narxi. Valyuta: USD
54.48
-1.05 (-1.89%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
54.48
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
54.48
-1.05 (-1.89%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
54.48
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Xenon Pharmaceuticals Inc. neyroshunoslikka ixtisoslashgan biofarmatsevtika kompaniyasi bo'lib, nevrologik va psixiatrik kasalliklari bo'lgan bemorlarni davolash uchun terapevtik vositalarni kashf qilish, ishlab chiqish va taqdim etish bilan shug'ullanadi. Uning mahsulot nomzodlari orasida Azetukalner, yangi, kuchli Kv7 kaliy kanal ochuvchisi mavjud bo'lib, u epilepsiyani, shu jumladan fokal boshlanadigan tutqanoqlar va birlamchi generalizatsiya qilingan tonik-klonik tutqanoqlarni, shuningdek, katta depressiv buzuqlik va bipolyar depressiya kabi neyropsixiatrik kasalliklarni davolash uchun 3-bosqichli klinik rivojlanishda. Bundan tashqari, kompaniyaning 1-bosqichli bir martalik ko'tarilgan dozali/ko'p martalik ko'tarilgan dozali mahsulotlari orasida og'riqni davolash uchun natriy kanaliga yo'naltirilgan XEN1701 va Kv7 kaliy kanaliga yo'naltirilgan XEN1120 mavjud. Kompaniya ma'lum bir turdagi epilepsiyani davolash uchun 1-bosqichli klinik sinovlarda bo'lgan Nav1.2/1.6 natriy kanal inhibitori NBI-921355ni ishlab chiqish uchun Neurocrine Biosciences, Inc. bilan litsenziyalash va hamkorlik shartnomasiga ega. Xenon Pharmaceuticals Inc. 1996 yilda ro'yxatga olingan va shtab-kvartirasi Kanadaning Burnabi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher John Kenney M.D. | Chief Medical Officer |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation |
| J.P. Gilbert | Senior Director |
| Mr. Darren S. Cline M.B.A. | Chief Commercial Officer and Member of Executive Team |
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO, Principal Accounting Officer & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-13 | 8-K | xene-20260313.htm |
| 2026-03-12 | 8-K | d97906d8k.htm |
| 2026-03-09 | 8-K | d107087d8k.htm |
| 2025-12-01 | 8-K | xene-20251124.htm |
| 2025-11-03 | 10-Q | xene-20250930.htm |
| 2025-10-17 | 8-K/A | xene-20251015.htm |
| 2025-10-16 | 8-K | xene-20251015.htm |
| 2025-08-11 | 8-K | xene-20250811.htm |
| 2025-07-03 | 8-K | xene-20250630.htm |
| 2025-06-05 | 8-K | xene-20250604.htm |
| Mr. Thomas Patrick Kelly J.D. | Chief Financial Officer |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Shelley McClCoskey B.A. | Executive Vice President of Human Resources |